Skip to content
AnalystLens

Welltower Annual Report, Year Ended Dec 31, 2019

Filing Date
Filed February 14, 2020
Period End
December 31, 2019
Security
WELL
In the record · 2016–202610-K1110-Q338-K160

WELL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 160 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Feb ’17Feb ’17
  2. Leadership change8-K · May ’19May ’19
  3. Change in control8-K · May ’22May ’22
  4. Material agreement8-K · Mar ’26Mar ’26

Summary

Summary of the 10-K filed February 14, 2020. Cited figures are marked; the original filing is the authoritative source.

Welltower Inc. (NYSE: WELL) closed 2019 with record scale: total revenues rose 9% to $5.12 billiona, net income reached $1.33 billion, and net income attributable to common stockholders grew 62% to $1.23 billion.

Consolidated NOI increased 7% to $2.43 billionb, and FFO per diluted share rose 5% to $3.91. Growth was driven largely by acquisitions, with roughly $4.0 billion of real estate acquired in 2019, most notably the $1.25 billion CNL Healthcare outpatient medical portfolio, partially offset by $2.7 billion of dispositions, including the sale of the Benchmark Senior Living portfolio at a $520 million gain. The company's portfolio is now split across Seniors Housing Operating (43% of NOI), Triple-net (38%), and Outpatient Medical (19%), with exposure concentrated in the U.S., U.K., and Canada.

Balance sheet leverage moved higher. Net debt to book capitalization rose to 46.5% from 45.0%, and adjusted interest coverage was steady at 4.14x. Management nonetheless kept the 2020 annual dividend flat at $3.48c per share, a 195th consecutive quarterly payment, and funded growth through a mix of senior unsecured notes, the equity shelf program, and forward sales.

Same-store NOI was essentially flat for Seniors Housing Operating (-0.2%d) and Triple-net (+1.5%), while Outpatient Medical same-store NOI grew 1.1%, so most growth came from acquisitions rather than organic performance. Key risks flagged in the filing include operator concentration (Sunrise Senior Living, ProMedica, and Genesis HealthCare), exposure to Medicare and Medicaid reimbursement policy, Brexit and currency effects on U.K. and Canadian operations, the expected discontinuance of LIBOR after 2021, and the company's reliance on operators' ability to pay rent. Ernst & Young issued an unqualified opinion on both the financial statements and internal controls, and no material weaknesses were reported.

Key Highlights

  1. Total revenues grew 9% to $5.12 billion in 2019, and net income attributable to common stockholders rose 62% to $1.23 billion.
  2. Consolidated NOI increased 7% to $2.43 billion, with Seniors Housing Operating contributing 43%, Triple-net 38%, and Outpatient Medical 19%.
  3. FFO attributable to common stockholders reached $1.58 billion, or $3.91 per diluted share, up 5% year over year.
  4. Acquisitions totaled roughly $4.0 billion, including the $1.25 billion CNL Healthcare outpatient medical portfolio, while $2.7 billion of dispositions produced a $748 million gain on real estate sales.
  5. Net debt to book capitalization increased to 46.5% from 45.0%, and adjusted interest coverage held at 4.14x, indicating a modest rise in leverage.
  6. The 2020 dividend was held flat at $3.48 per share, and same-store NOI was essentially flat for Seniors Housing Operating (-0.2%), indicating growth is acquisition-driven.
  7. Concentration risk remains significant, with Sunrise, ProMedica, Revera, and Genesis together representing roughly 37% of consolidated NOI.

Financial Statements

FY2019 against FY2018

Line itemFY2019FY2018Change
Revenue$5.12B$4.70B+9.0%
Cost of Revenue$2.69B$2.43B+10.6%
Gross Profit$2.43B$2.27B+7.2%
SG&A Expenses$126.55M$126.38M+0.1%
Operating Expenses$4.58B$4.28B+7.0%
Interest Expense$555.56M$526.59M+5.5%
Net Income$1.23B$758.25M+62.5%
EPS (Basic)$3.07$2.03+51.2%
EPS (Diluted)$3.05$2.02+51.0%
Shares Outstanding (Basic)401.85M373.62M+7.6%
Shares Outstanding (Diluted)403.81M375.25M+7.6%

Frequently Asked Questions

  1. How did Welltower's earnings and cash flow perform in 2019?

    Net income attributable to common stockholders was $1.23 billion, or $3.05 per diluted share, versus $758 million in 2018. The increase was driven largely by $748 million of gains on real estate dispositions, including the Benchmark Senior Living sale. Operating cash flow was $1.54 billion, slightly below 2018's $1.58 billion, and it exceeded cash distributions to stockholders of $1.40 billion.

  2. Is the dividend safe, and how is it covered?

    The 2020 annual dividend was set at $3.48 per share, unchanged from 2019. Operating cash flow of $1.54 billion comfortably exceeds the $1.40 billion of common dividends paid in 2019, and the company reports that cash flows have exceeded distributions in each of the last three years. The REIT distribution requirement is also described as satisfied. Dividend growth, however, has been absent, so investors looking for increases should note the flat payout.

  3. What are the main concentration and tenant risks?

    Sunrise Senior Living (14% of NOI, managed properties), ProMedica (9%, master lease on 218 properties with an 80% joint venture interest), Revera (6%), and Genesis HealthCare (5%) are the largest relationships. Genesis also has loans with a $296 million net balance, and the company recorded $18.7 million in loan loss provisions and $62.97 million in 2017 related to Genesis-linked loans. Failure by any of these operators to pay rent or manage properties effectively could materially affect results.

  4. How exposed is Welltower to leverage and interest rate changes?

    Total debt and lease obligations were about $15.4 billion at year end, with $3.47 billion of variable-rate debt. A 1% rise in rates would increase annual interest expense by about $34.7 million. The company has used interest rate swaps and caps to manage this exposure, and it plans to refinance floating-rate borrowings into long-term fixed-rate notes. Its primary unsecured credit facility carries a $3 billion capacity, of which $945 million was drawn on the revolver and $643.6 million was outstanding in commercial paper.